Previous work demonstrated that tumor‐derived exosomes (TEX) harbor both neoantigens and TAAs.[85] However, solely immunizing with TEX merely induced satisfied antitumor immunity due to the limited immunogenicity and immunosuppressive TME.[86] Several approaches, such as genetic engineering, physical embedding, and surface protein conjugating, have been employed to co‐deliver multiple adjuvants or immunomodulators to improve the efficacy. The gene discussed is ERVW-1; the disease is neoplasm.